07:00 , Sep 28, 2009 |  BC Week In Review  |  Clinical News

Blood-based colorectal cancer screening test: Feasibility study data

Data from a feasibility study of blood samples from 124 colorectal cancer patients and 444 control patients undergoing colonoscopy for cancer screening showed that OncoMethylome's blood-based colorectal cancer screening test had 58% sensitivity and 90%...
07:00 , Sep 28, 2009 |  BioCentury  |  Finance

Ebb & Flow

The pair of life sciences companies on IPO road shows may give investors and other companies clues on the opening of an IPO window. Profitable plasma-derived protein company Talecris Biotherapeutics Inc. may price this week,...
01:11 , Sep 22, 2009 |  BC Extra  |  Clinical News

OncoMethylome gains on CRC data

OncoMethylome Sciences S.A. (Euronext:ONCOB) gained EUR 0.63 (11%) to EUR 6.60 on Monday after reporting that its blood-based colorectal cancer screening test had 58% sensitivity and 90% specificity for methylated spectrin repeat containing nuclear envelope...